<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From June 1996 to January 2001, 91 patients with B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> up to 18 years of age were enrolled in Tokyo Children's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Study Group (TCCSG) NHL B9604 protocol study </plain></SENT>
<SENT sid="1" pm="."><plain>Five-day intensive chemotherapy courses including high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> were used for <z:e sem="disease" ids="C0277565" disease_type="Disease or Syndrome" abbrv="">localized disease</z:e> (Groups A and B) </plain></SENT>
<SENT sid="2" pm="."><plain>High-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> was added for advanced disease (Groups C and D) </plain></SENT>
<SENT sid="3" pm="."><plain>Fifteen patients experienced an adverse event </plain></SENT>
<SENT sid="4" pm="."><plain>There were three induction failures, eight relapses (three local, four bone marrow (BM), one BM + local), two toxic <z:hpo ids='HP_0011420'>deaths</z:hpo> and two second malignant <z:hpo ids='HP_0002664'>neoplasm</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Event-free survival at 6 years in Group D and in <z:hpo ids='HP_0000001'>all</z:hpo> patients was 82.4% +/- 9.2% and 81.9% +/- 4.4%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The TCCSG NHL B9604 protocol achieved an excellent treatment outcome especially in patients with the most advanced disease (Group D: high BM blast cell burden and/or central <z:mp ids='MP_0008912'>nervous</z:mp> system involvement) </plain></SENT>
</text></document>